UNCY logo

UNCY
Unicycive Therapeutics Inc

3,121
Mkt Cap
$175.91M
Volume
309,316.00
52W High
$11.00
52W Low
$3.71
PE Ratio
-3.45
UNCY Fundamentals
Price
$6.90
Prev Close
$6.97
Open
$6.97
50D MA
$6.67
Beta
0.79
Avg. Volume
456,861.01
EPS (Annual)
-$1.67
P/B
5.10
Rev/Employee
$0.00
$50.60
Loading...
Loading...

About

Unicycive Therapeutics, Inc. is a biotechnology company, which engages in developing novel treatments for kidney diseases. The firm investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
21

Frequently Asked Questions

What is Market Cap of Unicycive Therapeutics Inc?
What is the 52-week high for Unicycive Therapeutics Inc?
What is the 52-week low for Unicycive Therapeutics Inc?
What is Unicycive Therapeutics Inc stock price today?
What was Unicycive Therapeutics Inc stock price yesterday?
What is the PE ratio of Unicycive Therapeutics Inc?
What is the Price-to-Book ratio of Unicycive Therapeutics Inc?
What is the 50-day moving average of Unicycive Therapeutics Inc?
How many employees does Unicycive Therapeutics Inc have?

Latest UNCY News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.